Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
High sympathetic activity and alterations in nitric oxide synthesis attributable to accumulation of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) have recently been identified as potential causal mechanisms for the high cardiovascular mortality rates among patients with ESRD. The link between these risk factors has not been studied. Therefore, the relationship between plasma norepinephrine (NE) and ADMA levels was examined in a large cohort of hemodialysis patients (n = 224), and whether these factors interacted in predicting all-cause mortality and new cardiovascular event rates among those patients was investigated. Plasma ADMA levels were strongly associated with plasma NE levels (P < 0.001) and to a lesser extent with heart rate (P < 0.01). In multivariate analyses, the ADMA-NE correlation was observed to be independent of age, gender, serum albumin levels, arterial pressure and antihypertensive treatment, duration of dialysis treatment, diabetes mellitus, and other risk factors. NE was an independent significant predictor of both death and cardiovascular events in Cox models not including ADMA. However, when ADMA was introduced into those models, NE became a largely nonsignificant predictor of those outcomes, whereas plasma ADMA levels emerged as a highly significant predictor of both death (P < 0.001) and cardiovascular events (P < 0.001). These findings suggest that ADMA is an intervening factor in the causal pathway leading to those outcomes. Plasma NE and ADMA concentrations are strongly related among patients with ESRD. These two factors are likely to be involved in the same causal pathway leading to death and cardiovascular events among those patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., et al. (2002) · Circulation · doi:10.1161/hc1102.105261 · Cited by 519 · cited 2×
“Levels of both NE (7) and ADMA (8) predict adverse cardiovascular outcomes among hemodialysis patients and are strongly associated with left ventricular concentric hypertrophy and left ventricular systolic dysfunction (9,10).”
BackgroundSelf-citationAdvanced glycation end products and mortality in hemodialysis patients
Schwedler, S. B., Metzger, T., Schinzel, R., & Wanner, C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00423.x · Cited by 195 · cited 1×
“Although the relative contributions of traditional and emerging risk factors are still debated, there is a consensus that ESRD is a situation of unique epidemiologic complexity (3), because traditional risk factors, such as arterial pressure (4), cholesterol levels (5), and advanced glycation end product levels (6), d…”
Background
Cited by
Chronic Kidney Disease: Effects on the Cardiovascular System
Schiffrin, E. L., Lipman, M. L., & Mann, J. F. E. (2007) · Circulation · doi:10.1161/circulationaha.106.678342 · Cited by 1,448
Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure
Grassi, G., Quarti-Trevano, F., Seravalle, G., Arenare, F., Volpe, M., Furiani, S., Dell'Oro, R., & Mancia, G. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.164780 · Cited by 311
Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment
Neumann, J., Ligtenberg, G., Klein, I. I., Koomans, H. A., & Blankestijn, P. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00552.x · Cited by 304
The role of asymmetric and symmetric dimethylarginines in renal disease
Schwedhelm, E., & Böger, R. H. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.31 · Cited by 260
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Kaur, J., Young, B., & Fadel, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081682 · Cited by 168
Metadata
- Authors
- Mallamaci, F., Tripepi, G., Maas, R., Malatino, L., Bo[Combining Diaeresis]ger, R., & Zoccali, C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2004-02
- Volume
- 15
- Issue
- 2
- Pages
- 435-441
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2153081833
- Cited by
- 96
- References
- 4
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. https://app.cochat.ai/papers/10.1097/01.asn.0000106717.58091.f6
- The paper
- Mallamaci, F., Tripepi, G., Maas, R., Malatino, L., Bo[Combining Diaeresis]ger, R., & Zoccali, C. (2004). Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000106717.58091.f6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.